OpenURL Connection Search

Select item for more details and to access through your institution.

Defining the next generation of severe malaria treatment: a target product profile.
Published in:
Malaria Journal, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12936-024-04986-z
By:
- Achan, Jane;
- Barry, Aïssata;
- Leroy, Didier;
- Kamara, George;
- Duparc, Stephan;
- Kaszubska, Wiweka;
- Gandhi, Preetam;
- Buffet, Bénédicte;
- Tshilab, Patrick;
- Ogutu, Bernhards;
- Taylor, Terrie;
- Krishna, Sanjeev;
- Richardson, Naomi;
- Ramachandruni, Hanu;
- Rietveld, Hans
Publication type:
Article
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Published in:
Multiple Sclerosis Journal, 2022, v. 28, n. 3, p. 429, doi. 10.1177/13524585211024997
By:
- Hartung, Hans-Peter;
- Derfuss, Tobias;
- Cree, Bruce AC;
- Sormani, Maria Pia;
- Selmaj, Krzysztof;
- Stutters, Jonathan;
- Prados, Ferran;
- MacManus, David;
- Schneble, Hans-Martin;
- Lambert, Estelle;
- Porchet, Hervé;
- Glanzman, Robert;
- Warne, David;
- Curtin, Francois;
- Kornmann, Gabrielle;
- Buffet, Bénédicte;
- Kremer, David;
- Küry, Patrick;
- Leppert, David;
- Rückle, Thomas
Publication type:
Article
A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.
Published in:
Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1111, doi. 10.1111/dom.14010
By:
- Curtin, Francois;
- Champion, Bernard;
- Davoren, Peter;
- Duke, Sally;
- Ekinci, Elif I.;
- Gilfillan, Chris;
- Morbey, Claire;
- Nathow, Thomas;
- O'Moore‐Sullivan, Trisha;
- O'Neal, David;
- Roberts, Adam;
- Stranks, Stephen;
- Stuckey, Bronwyn;
- Vora, Parind;
- Malpass, Sam;
- Lloyd, David;
- Maëstracci‐Beard, Nicole;
- Buffet, Bénédicte;
- Kornmann, Gabrielle;
- Bernard, Corinne
Publication type:
Article

Found: 3

Defining the next generation of severe malaria treatment: a target product profile.

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.

A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.